- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01883206
CMV Glycoprotein B (gB) Vaccine Long Term Antibody Response
Long Term Antibody Response to CMV gB Vaccine in Patients Requiring Liver or Renal Transplant.
The purpose of this study is to see how well the antibody levels found months to years after patients entered a previous randomised placebo-controlled trial of a glycoprotein B vaccine against cytomegalovirus have persisted and to have the previous samples retested using different methods which have been further developed in different laboratories.
Also, to prepare monoclonal antibodies from the B lymphocytes of these patients and define their strength. If potent antibodies are identified, the investigators would like to consider developing them further to see if they can protect future transplant patients against cytomegalovirus.
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
London, United Kingdom, NW3 2QG
- Royal Free Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Recipient of IMP (Investigational Medicinal product) (CMV gB vaccine or placebo) in trial 'Phase II Immunogenicity Trial Of Cytomegalovirus Glycoprotein B Vaccine In Allograft Candidate Recipients Study' (CTA ref no 20363/0238/001-0010; REC ref no 5476; UCL sponsor no 05/009).
- Informed consent must be obtained from the patient.
Exclusion Criteria:
1. Patient unable or unwilling to provide and sign an informed consent.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Other
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The primary outcome measure will be anti-gB titre level.
Time Frame: Day 1.
|
The first exploratory analysis will plot antibody titre against time since RCT (Random Control Trial) enrolment by study group.
This will be examined visually to ensure that it is reasonable to group together samples measured at different time points after the original RCT completed.
|
Day 1.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Titre of antibodies able to neutralise CMV.
Time Frame: Day 1.
|
Ability of monoclonal antibodies prepared from patients' B cells to neutralise CMV and to bind to glycoprotein B in an enzyme immunoassay.
|
Day 1.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Paul D Griffiths, UCL
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- UCL 12/0161
- 2012-002767-95 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Viraemia
-
University College, LondonCompleted
-
University Health Network, TorontoCompletedCytomegalovirus ViraemiaCanada
-
University Health Network, TorontoCanadian National Transplant Research ProgramCompletedCytomegalovirus ViraemiaSpain, Canada
-
University of AthensUnknownStress, Physiological | Cytomegalovirus Viraemia | Receptor, Hormonal; Disorder | Other Deficiency of Cell-mediated ImmunityGreece
-
Assistance Publique - Hôpitaux de ParisInstitut National de la Santé Et de la Recherche Médicale, FranceCompletedHematologic Diseases | Allogeneic Disease | Epstein-Barr ViraemiaFrance
-
University of AarhusAarhus University HospitalCompletedEpstein-Barr Virus Infections | Post-transplant Lymphoproliferative Disorder | Hemophagocytic Lymphohistiocytoses | Epstein-Barr Virus-Related Hodgkin Lymphoma | Epstein-Barr Virus-Related Non-Hodgkin Lymphoma | Mononucleosis | Epstein-Barr Virus Related Malignancy | Epstein-Barr Viraemia | Hemophag...Denmark
-
Atara BiotherapeuticsMerck Sharp & Dohme LLCTerminatedNasopharyngeal Carcinoma | Nasopharyngeal Neoplasms | Epstein-Barr Virus Infections | Epstein-Barr Viraemia | Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)United States